Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. (Q36529784)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Sergio Amadori

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

3

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Tommaso Caravita

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Mario Boccadoro

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 July 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

374-387

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

The ubiquitin-proteasome pathway in cancer

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

The proteasome: structure, function, and role in the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

The ubiquitin-proteasome pathway and its role in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

The proteasome--an emerging therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Potential for proteasome inhibition in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Proteasome inhibitors: from research tools to drug candidates

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

NF-kappa B as a therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Development of the proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

An information-intensive approach to the molecular pharmacology of cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Molecular pathways that modify tumor radiation response

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Declining stroke rates in Californian children with sickle cell disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Phase I study of bortezomib in refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Proteasome inhibition in oxidative stress neurotoxicity: implications for heat shock proteins.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0555

7 January 2021

Identifiers

DOI

10.1038/NCPONC0555

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16826218%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference